Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents

  • Brindisi, Margherita
  • Ulivieri, Cristina
  • Alfano, Gloria
  • Gemma, Sandra
  • Balaguer, Francisco de Asís
  • Khan, Tuhina
  • Grillo, Alessandro
  • Chemi, Giulia
  • Menchon, Grégory
  • Prota, Andrea E.
  • Olieric, Natacha
  • Lucena-Agell, Daniel
  • Barasoain, Isabel
  • Díaz, José Fernando
  • Nebbioso, Angela
  • Conte, Mariarosaria
  • Lopresti, Ludovica
  • Magnano, Stefania
  • Amet, Rebecca
  • Kinsella, Paula
  • Zisterer, Daniela M.
  • Ibrahim, Ola
  • O'Sullivan, Jeff
  • Morbidelli, Lucia
  • Spaccapelo, Roberta
  • Baldari, Cosima T.
  • Butini, Stefania
  • Novellino, Ettore
  • Campiani, Giuseppe
  • Altucci, Lucia
  • Steinmetz, Michel O.
  • Brogi, Simone
Microtubule-targeting agents (MTAs) are a class of clinically successful anti-cancer drugs. The emergence of multidrug resistance to MTAs imposes the need for developing new MTAs endowed with diverse mechanistic properties. Benzoxazepines were recently identified as a novel class of MTAs. These anticancer agents were thoroughly characterized for their antitumor activity, although, their exact mechanism of action remained elusive. Combining chemical, biochemical, cellular, bioinformatics and structural efforts we developed improved pyrrolonaphthoxazepines antitumor agents and their mode of action at the molecular level was elucidated. Compound 6j, one of the most potent analogues, was confirmed by X-ray as a colchicine-site MTA. A comprehensive structural investigation was performed for a complete elucidation of the structure-activity relationships. Selected pyrrolonaphthoxazepines were evaluated for their effects on cell cycle, apoptosis and differentiation in a variety of cancer cells, including multidrug resistant cell lines. Our results define compound 6j as a potentially useful optimized hit for the development of effective compounds for treating drug-resistant tumors., This work was supported in part by a grant from the Swiss National Science Foundation (31003A_166608; to M.O.S), grant BFU2016-75319-R (AEI/FEDER, EU) from Ministerio de Economia y Competitividad, Blueprint 282510, AIRC-17217. The authors acknowledge networking contribution by the COST Action CM1407 “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” (to M.O.S. and J.F.D.) and the COST Action EPICHEMBIO CM-1406 (to L.A. and G.C.). This work has also received partial funding from the European Union’s Horizon 2020 (EU) research and innovation programme under the Marie Sklodowska-Curie grant agreement No 721906. Finally, this work was partially funded by MIUR-PRIN project n. 2015Y3C5KP (to L.M.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy

  • Campiani, Giuseppe
  • Khan, Tuhina
  • Ulivieri, Cristina
  • Staiano, Leopoldo
  • Papulino, Chiara
  • Magnano, Stefania
  • Nathwani, Seema
  • Ramunno, Anna
  • Lucena-Agell, Daniel
  • Relitti, Nicola
  • Federico, Stefano
  • Pozzetti, Luca
  • Carullo, Gabriele
  • Casagni, Alice
  • Brogi, Simone
  • Vanni, Francesca
  • Galatello, Paola
  • Ghanim, Magda
  • McCabe, Niamh
  • Lamponi, Stefania
  • Valoti, M.
  • Ibrahim, Ola
  • O'Sullivan, Jeff
  • Turkington, Richard
  • Kelly, Vincent P.
  • VanWemmel, Ruben
  • Díaz, José Fernando
  • Gemma, Sandra
  • Zisterer, Daniela M.
  • Altucci, Lucia
  • De Matteis, Antonella
  • Butini, Stefania
  • Benedetti, Rosaria
96 p.-20 fig.-7 tab., Autophagy is a lysosome dependent cell survival mechanism and is central to the maintenance of organismal homeostasis in both physiological and pathological situations. Targeting autophagy in cancer therapy attracted considerable attention in the past as stress-induced autophagy has been demonstrated to contribute to both drug resistance and malignant progression and recently interest in this area has re-emerged. Unlocking the therapeutic potential of autophagy modulation could be a valuable strategy for designing innovative tools for cancer treatment. Microtubule-targeting agents (MTAs) are some of the most successful anti-cancer drugs used in the clinic to date. Scaling up our efforts to develop new anti-cancer agents, we rationally designed multifunctional agents 5a-l with improved potency and safety that combine tubulin depolymerising efficacy with autophagic flux inhibitory activity. Through a combination of computational, biological, biochemical, pharmacokinetic-safety, metabolic studies and SAR analyses we identified the hits 5i,k. These MTAs were characterised as potent pro-apoptotic agents and also demonstrated autophagy inhibition efficacy. To measure their efficacy at inhibiting autophagy, we investigated their effects on basal and starvation-mediated autophagic flux by quantifying the expression of LC3II/LC3I and p62 proteins in oral squamous cell carcinoma and human leukaemia through western blotting and by immunofluorescence study of LC3 and LAMP1 in a cervical carcinoma cell line. Analogues 5i and 5k, endowed with pro-apoptotic activity on a range of hematological cancer cells (including ex-vivo chronic lymphocytic leukaemia (CLL) cells) and several solid tumor cell lines, also behaved as late-stage autophagy inhibitors by impairing autophagosome-lysosome fusion., This research was funded by the European Union's Horizon 2020 (EU) Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No.721906-TRACT (TK, SM, MG, NMcC, GO’S, RT, VK, SG, DZ, GC, SB); Tuscany strategic project POR-FSE 2014-2020, ‘Medicina di Precisione e Malattie Rare’(MePreMaRe), (ACE-ESCC) (NR, GC, SB), and by “Epigenetic Hallmarks of Multiple Sclerosis” (acronym Epi-MS) (id:415, Merit Ranking Area ERC LS) in VALERE 2019 Program; V:ALERE 2020 – Progetto competitivo “CIRCE” in risposta al bando D.R. n. 138 del February 17, 2020 Program; Blueprint 282510; EPICHEMBIO CM1406; AIRC-17217; VALERE: Vanvitelli per la Ricerca; Campania Regional Government Technology Platform Lotta alle Patologie Oncologiche: iCURE; Campania Regional Government FASE2: IDEAL. MIUR, Proof of Concept POC01_00043. POR Campania FSE 2014-2020 ASSE III., Peer reviewed